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Background: Osteoarthritis of the hands is a prevalent musculoskeletal disease with a considerable effect on
patients’ lives, but knowledge and research results in the field of hand osteoarthritis are limited. Therefore, the
Disease Characteristics in Hand OA (DICHOA) initiative was founded in early 2005 with the aim of
addressing key issues and facilitating research into hand osteoarthritis.
Objective: To review and discuss current knowledge on hand osteoarthritis with regard to aetiopathogenesis,
diagnostic criteria, biomarkers and clinical outcome measures.
Methods: Recommendations were made based on a literature review.
Results: Outcomes of hand osteoarthritis should be explored, including patient perspective on the separate
components of disease activity, damage and functioning. All imaging techniques should be cross-validated
for hand osteoarthritis with clinical status, including disease activity, function and performance, biomarkers
and long-term outcome. New imaging modalities are available and need scoring systems and validation. The
role of biomarkers in hand osteoarthritis has to be defined.
Conclusion: Future research in hand osteoarthritis is warranted.
O
steoarthritis of the hands is one of the most prevalent
musculoskeletal diseases. The disease leads to pain in
and around affected joints and to swelling, stiffness,
deformity and gradual loss of function.1 2 Contrary to common
belief, it is not necessarily a disease of older people, but can
occur relatively early in life, impairing the patient’s capacity to
work. Currently, the detailed pathogenetic events are unknown,
and therapy is confined to symptomatic treatment or surgical
intervention. Because research activities in osteoarthritis have
concentrated on the knee and hip in recent years, knowledge
and research results for hand osteoarthritis are limited. Hand
joints are frequently involved in combination with osteoarthri-
tis elsewhere; however, such ‘‘generalised osteoarthritis’’ may
be a function of age rather than representing a generalised
nature of the disease.
Given the impact of hand osteoarthritis together with limited
research data, the Disease Characteristics in Hand OA
(DICHOA) initiative was founded in early 2005 with the aim
of addressing key issues and facilitating research into hand
osteoarthritis. In this article, we review and discuss current
knowledge of the aetiopathogenesis, diagnostic criteria, bio-
markers and outcome measures for clinical, epidemiological
and follow-up studies, and the therapeutic interventions for
hand osteoarthritis to facilitate the development of strategies
addressing these issues.
CURRENT DIAGNOSTIC CRITERIA FOR HAND
OSTEOARTHRITIS
The criteria for hand osteoarthritis are not clear. In hand
osteoarthritis studies, especially epidemiological studies, several
sets of criteria are used, none scientifically tested. Both
radiographic and clinical criteria sets are applied. Some criteria
sets are based on the involvement of various or a particular
number of joint groups comprising proximal interphalangeal
joints (PIPs), distal interphalangeal joints (DIPs) or first
carpometacarpal joints (CMCs), whereas others require the
involvement of only one hand joint with osteoarthritis.
A validated criteria set for hand osteoarthritis is the
classification defined by the committee on Diagnostic and
Therapeutic Criteria of the American College of Rheumatology
(ACR).3 These criteria were developed by comparing patients
with clinical hand osteoarthritis, as determined by experts, with
patients suffering from other rheumatic disorders causing hand
pain such as rheumatoid arthritis (box 1).
These classification criteria have a sensitivity of 0.94 and a
specificity of 0.87 in this setting. Pain had to be present on most
days of the month before the analysis to fulfil these criteria.
However, for epidemiological studies, the need for pain on most
Abbreviations: ACR, American College of Rheumatology; AUSCAN,
Australian/Canadian Osteoarthritis Hand Index; CMC, carpometacarpal
joints; DICHOA, Disease Characteristics in Hand OA; DIP, distal
interphalangeal joint; MCP, metacarpophalangeal joints; PIP, proximal
interphalangeal joint; SACRAH, Score for the Assessment and
Quantification of Chronic Rheumatoid Affections of the Hands
Box 1: American College of Rheumatology criteria
for osteoarthritis of the hand
Hand pain, aching or stiffness for most days of the prior month
plus 3 of the following 4 criteria:
N Hard tissue enlargement of >2 of 10 selected hand
joints*
N Metacarpophalangeal joint swelling in (2 joints
N Hard tissue enlargement of >2 distal interphalangeal
joint joints
N Deformity of >1 of 10 selected hand joints
*The 10 selected hand joints include bilateral second and
third DIP joints, second and third proximal interphalangeal
joints and first carpometacarpal joints.
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days of the previous month may lead to lack of sensitivity and
instability of the diagnosis. If clear-cut changes of hand
osteoarthritis are clinically evident, the frequent presence of
pain would suggest a certain degree of disease activity rather
than being a defining diagnostic criterion. Another discussion
point is that the ACR classification criteria for hand osteoar-
thritis combined all joint groups in the hand, so that patients
with only two DIPs with two first CMCs affected fulfil the
criteria, even though these patients may represent different
disease entities, requiring different treatment strategies. Hence,
it may be more accurate if all (affected) joints in the hand were
to be described separately and that, depending on the research
question or intervention under study, the assessment of
changes observed in specific hand joints might be required.
The requirement for the presence of a certain number of
affected joints, as per the ACR classification criteria, is not
supported by other research data. From a clinical point of view,
it has been suggested that in therapeutic studies of hand
osteoarthritis patients with one painful osteoarthritic hand
joint could be included.
Although radiographs did not add information for the clinical
patient population used for the ACR classification of hand
osteoarthritis, it has been suggested that this could be different
in other study populations. Moreover, Heberden nodes on
physical examination are not always equivalent to osteophytes
at DIPs on radiographs. Hence, it may be valuable to add
radiographs to collect extra information. Recently a European
League Against Rheumatism task force was set up to define a
diagnostic criteria set for hand osteoarthritis, which it is hoped
will resolve these problems.
Although most studies in osteoarthritis investigate one
affected joint site in any given patient, often more joint sites
are affected simultaneously.4 5 A concept of generalised
osteoarthritis was suggested from data showing that multiple
joint involvement was observed more frequently than expected
by chance6–9 and that joints are not affected at random.10 11 This
can be seen in the hands themselves but also in all the other
joints. How hand osteoarthritis is related to osteoarthritis in
other joint sites is unclear. Kellgren and Moore defined in 1952
a distinct clinical entity for which they suggested the name of
primary generalised osteoarthritis, which was associated with
Heberden nodes.12 To define this entity, radiographic osteoar-
thritis in 13 joint groups was assessed and a cut-off point was
set rather arbitrarily as involvement of at least 3 or 5 affected
joint groups.13 This definition is still widely used.14 When using
this definition, hand osteoarthritis can be defined as general-
ised osteoarthritis. Alternative definitions for generalised
osteoarthritis especially in epidemiological studies are the
presence of Heberden nodes.
The generalised nature of osteoarthritis is underlined by data
from a Norwegian hand osteoarthritis population, which
comprised 199 patients, included in this study on the basis of
clinically diagnosed hand osteoarthritis. In total, 82% fulfilled
the ACR classification criteria for hand osteoarthritis, 10%
fulfilled the clinical and radiographic ACR classification criteria
for hip osteoarthritis and 11 patients had undergone a hip
replacement. Most (75%) fulfilled the clinical ACR classifica-
tion criteria for knee osteoarthritis, and 7 patients had
undergone a knee replacement.15 This stresses the importance
of incorporating information concerning all joint groups in a
patient when investigating hand osteoarthritis and in defining
the osteoarthritis phenotype.
RISK FACTORS FOR DEVELOPMENT OF HAND
OSTEOARTHRITIS
Much more is known about risk factors for development of
osteoarthritis of the knees and hips than for osteoarthritis of
the hands. However, some undisputable risk factors have been
identified.16 Age seems to be the strongest risk factor for both
radiographic and symptomatic hand osteoarthritis,17 18 although
only up to the age of 75 years.19 Body mass index is positively
associated with osteoarthritis of the hand,16 20 21 but the reason
for this association is currently unknown. Biomechanical
influences have been suggested as risk factors for hand
osteoarthritis but the evidence is rather weak.22 23 As for other
subtypes of osteoarthritis of the peripheral joints, tobacco
smoking seems to decrease the risk for development even after
adjustment for body mass index.16
Familial aggregation of Heberden nodes was described as
early as the 1940s24 and has since been confirmed for hand
osteoarthritis by several studies.16 25 Genetic factors important
in the aetiopathogenesis were identified early in genetic
research by linking the COL2AI gene to familial osteoarthritis
developing at a young age.16 26 An association between
polymorphisms in the matrilin-3 gene and different subtypes
of hand osteoarthritis, idiopathic hand osteoarthritis and first
CMC osteoarthritis, has recently been recognised in two
separate study populations.27 28
IMAGING IN HAND OSTEOARTHRITIS
Plain radiographs are the initial method of choice to image the
hands, as they are widely available, cheap and reproducible.
The characteristic radiological features of osteoarthritis include
joint space narrowing, osteophytes, sclerosis and deformity. It is
not clear whether any or all these features are truly indicative of
osteoarthritis. Osteophytosis, without joint space narrowing,
can be present even after several years of follow-up, raising the
question of whether this condition should be addressed as
osteoarthritis.29 Radiographic features of osteoarthritis are often
seen in the hands, especially in elderly patients, in the absence
of symptoms, and so may represent age-related changes.30
Kessler et al31 suggested a hand scale for osteoarthritis in which
radiological osteoarthritis is defined only when joint space
narrowing is present.
To determine the nature and severity of osteoarthritis in
hand joints, several standardised qualitative scoring methods
can be used, including those described by Kellgren and
Lawrence,32 Kallman,33 and Altman.34 Many individual features
can be scored, but none of these methods distinguishes
between features of damage and repair.
The question arises as to which joints of the hands should be
scored. Usually, DIPs, PIPs and first CMCs are assessed in
published methods. Whether or not metacarpophalangeal joints
(MCPs) should be included is not clear. Further, it has not been
clarified whether erosive osteoarthritis is a distinct disease
entity or an aggressive variant of hand osteoarthritis.
Verbruggen and Veys35 36 developed a scoring method in which
erosive osteoarthritis is addressed. Currently, no validated
quantitative scoring method is available for hand osteoarthritis.
It is not clear which feature should be addressed, and with
regard to joint space width, it is unclear which part of the
interbone distance should be measured and how. Osteophytes
have been quantified by microfocal radiographic techniques,
but this method is not widely available.
MRI is a sensitive imaging method that has been extensively
evaluated in the knee, but scarcely in the hand. Methods are
being introduced to make the examination less uncomfortable
for the patient. At this stage it is also uncertain which tissue
types are the most relevant to examine (hyaline cartilage,
chondrophytes and osteophytes, synovium, joint effusion,
ligaments and capsule or bone-marrow oedema).37 A scoring
method has yet to be defined, tried and tested, although ‘‘whole
organ scores’’ , such as the Whole Organ Magnetic Resonance
imaging Score)38 and the Knee Osteoarthritis Scoring System39
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have been evaluated in the knee. It is still unknown which, if
any, individual radiological signs indicate the likelihood of
progression. Currently, it is felt that so-called bone-marrow
oedema is important.40 No tried and tested method of routinely
quantifying hyaline cartilage volume and bone-marrow oedema
in disease and health is currently available. The only imaging
technique with a known positive and negative predictive value
for progressive osteoarthritis is radionuclide imaging.41
However, this method carries a whole-body radiation burden,
and is not cheap or widely available. Currently, the develop-
ment of ultrasonography techniques for hand osteoarthritis is
necessary.42
BIOMARKERS
During processes leading to joint tissue destruction in
osteoarthritis, extracellular matrix proteins in cartilage, bone
and surrounding structures are degraded. Fragments are
released into synovial fluid and may subsequently reach the
circulation. Such fragments can be quantified by immunoas-
says, and these ‘‘molecular markers’’ have the potential to
provide information on ongoing active processes in the tissue.
Similarly, there are markers of protein formation within these
structures, which may reflect an increase in turnover or
attempted repair of damage. This technology has been
increasingly used both in osteoarthritis and in rheumatoid
arthritis as a means of diagnosis, for estimation of activity of
the tissue-damaging process, to document treatment effects
and, most importantly, to discover processes in the very early
stages of the disease to aid in prognostic considerations.43 44
Some of these applications have been more extensively studied
in rheumatoid arthritis, such as monitoring treatment effects,
as treatments with the potential to retard joint damage are
available for this disease.45 Table 1 shows some of the markers
currently being explored.
In osteoarthritis, most biomarker studies so far have been
performed on knee and to some extent in hip osteoarthritis, and
the reports predominantly concern studies of serum/plasma or
urine samples. Whether results from knee and hip osteoar-
thritis are applicable to osteoarthritis of the hands is unknown.
Given the fact that hand osteoarthritis is frequently accom-
panied by osteoarthritis in larger joints, it is also not clear
whether it is possible to discern changes reflecting processes in
the hands against a background of fragments released into the
circulation from other joints. A primary objective on the
research agenda would therefore be to explore whether
currently available markers and those in development may
prove useful in detecting these changes in carefully selected
patient groups. Novel markers with higher specificity for
osteoarthritis and/or markers that are released only in disease
states and not during normal turnover may prove parti-
cularly advantageous for monitoring hand osteoarthritis. It
should also be emphasised that advances in techniques for
analysis may allow future genetic studies, such as studies
with gene arrays of tissues or cells, microfluidic cards of specific
gene sets, and proteomic analysis of blood, synovial fluid or
urine.
Unless existing and promising novel approaches to bio-
marker identification and testing are applied to hand osteoar-
thritis, we will continue to have an imperfect appreciation of
how useful markers may be in assessing progression of the
disease, identifying patients who may benefit from poten-
tial disease-modifying therapy, and monitoring response to
therapy.
CLINICAL ACTIVITY AND OUTCOME MEASURES
Clinical measures are essential to monitor the disease process
and to evaluate the outcome. There is a lack of knowledge as to
which outcomes are important to patients with osteoarthritis.
If, from the perspective of patients, hand osteoarthritis is a
separate entity, outcomes specific for hand osteoarthritis
representing patient perspective should be defined. To date,
recommendations about which outcomes should be measured
have been derived from expert consensus. Clinical improve-
ment criteria for osteoarthritis in general have been defined
from clinical databases, but not specifically for hand osteoar-
thritis.46 In osteoarthritis in general, the recommendations for
assessments include pain, (physical) function and patient
global assessment.47–49 Specifically in hand osteoarthritis,
measurements of pain, function, performance, mobility, stiff-
ness, inflammation, deformity and aesthetic damage are
recommended.50
Pain can be measured with a visual analogue scale or a Likert
scale.46 Function and performance are included as separate
entities in the recommendations. Performance always requires
measurement by a ‘‘test’’, whereas either a ‘‘questionnaire’’ or a
‘‘test’’ can be used to measure function.46 For measurement of
performance, a hand function test is suggested, such as the
Backman hand function test,51 or grip-strength measurement.52
Questionnaires specifically developed and/or validated for
measurement of function in hand osteoarthritis53 include: the
Health Assessment Questionnaire,54 the Arthritis Impact
Measurement Scales-2 questionnaire,55 the Australian/
Canadian Osteoarthritis Hand Index (AUSCAN),56 57 the
Cochin scale,58 59 the Functional Index for Hand
Osteoarthritis,60 61 and the Score for the Assessment and
Quantification of Chronic Rheumatoid Affections of the
Hands (SACRAH).62 63 These questionnaires have mainly been
developed from lists of possible items pre-selected by profes-
sionals and then scored by the patients, but not from qualitative
studies exploring the perspective of patients with hand
osteoarthritis. It would be particularly advantageous to see
the AUSCAN questionnaire freely and publicly available for
academic use. A limitation of all questionnaires is the necessity
to translate and validate them for all regions with different
languages.
It has been suggested that physical functioning might
represent only one perspective of functioning, and a more
comprehensive perspective of functioning could include ‘‘parti-
cipation’’ in daily life as a key concept relevant to patients.
‘‘Participation’’ refers to a person’s relationship to other people
and involvement in societal institutions in the International
Classification of Functioning, Disability and Health.64 The
ability to perform a given task in a daily life situation may be
more important to a patient than their ability to perform a
Table 1 Currently available cartilage and bone
biomarkers
Cartilage Biomarker
Aggrecan G1 (hyaluronan-binding-region), chondroitin
sulphate region, chondroitin sulphate epitopes,
keratan sulphate, aggrecanase cleavage
neoepitopes, matrix metalloproteinase cleavage
neoepitopes
Type II collagen C-terminal propeptide, cross-links, collagenase
cleavage neoepitopes
Other matrix
molecules
Cartilage oligomeric matrix protein (thrombospondin
5), cartilage intermediate layer protein, matrilin-1
Bone
Type I collagen N-procollagen and C-procollagen propeptides, N-
telopeptides and C-telopeptides
Other matrix
molecules
Osteocalcin, bone sialoprotein
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specified task item in a test situation or on a questionnaire,
which may not be at all important to that particular patient.65 66
For measurement of mobility, range of motion is usually
assessed,67 although our experience suggests that range of
motion measurement may not have sufficient intra-rater
reliability for finger joints (data not shown). If mobility is
considered an issue important to the patients, a reliable tool or
a standardised protocol to increase the reliability should be
developed. Stiffness can be measured by the length of morning
stiffness or the stiffness subscales of the AUSCAN56 57 and the
SACRAH62 63 questionnaires, although it is not currently clear
whether stiffness is an outcome relevant to patients with hand
osteoarthritis.
Inflammation is assessed by joint swelling, night pain,
duration of morning stiffness or local erythema, regardless of
their clinical relevance, reliability or responsiveness.46 With
similarly questionable relevance, reliability and responsiveness,
measurement of deformity includes the presence or absence of
bone enlargement, Herberden and Bouchard nodes, and
squaring of first CMC or axial deviation. Measuring these
variables may require either standard protocols or validated
instruments.
Currently no tool exists for the measurement of aesthetic
damage, but there seems to be evidence in the literature that
this parameter is important to patients.46
Whether a domain represents the perspective of the patient
or the professional might influence the choice of instrument
and both should probably be included in any composite score.
Composite questionnaires, such as the AUSCAN56 57 or the
SACRAH,62 63 which include pain, stiffness and function,
represent only the perspective of the patient. Moreover, they
appear to combine aspects of long-term outcome and disease
activity. It may be more appropriate to separate measures of
disease activity from those of long-term outcome, and such
instruments need to be developed. Such scores should ideally
be multidimensional, composed of both subjective and objec-
tive components. Examples of a multidimensional approach,
using evaluation of disease activity, functional impairment and
imaging, can be found in other diseases, especially rheumatoid
arthritis, but also psoriatic arthritis and ankylosing spondyli-
tis,68 and have proven to be highly useful in linking aetiological,
clinical and treatment aspects.
GENERAL CONSIDERATIONS AND
RECOMMENDATIONS
We consider the following to be important for future research
in the field of hand osteoarthritis:
N Outcomes of hand osteoarthritis should be explored,
including the separate components of disease activity,
damage and functioning from a disease-specific and generic
health status perspective.
N All imaging modalities should be cross-validated in hand
osteoarthritis and related to clinical status, including disease
activity, function and performance, biomarkers and long-
term outcome.
N Several valid radiographic scoring systems exist: conclusive
comparative studies are needed.
N New imaging modalities are available and need scoring
systems and validation.
N Role of biomarkers in hand osteoarthritis has to be defined;
in this context, the specificity of markers has to be evaluated
in patients with osteoarthritis confined to the hands and
compared with polyarticular (‘‘generalised’’) osteoarthritis.
N Which outcome measures address most adequately the
outcomes important to patients with hand osteoarthritis?
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